Prosecution Insights
Last updated: April 19, 2026
Application No. 18/224,343

IMPLANTABLE MEDICAL DEVICE WITH PRIMARY COVERING AND SECONDARY COVERING

Final Rejection §103
Filed
Jul 20, 2023
Examiner
SCHWIKER, KATHERINE H
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
BOSTON SCIENTIFIC CORPORATION
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
3y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
271 granted / 408 resolved
-3.6% vs TC avg
Strong +36% interview lift
Without
With
+35.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
45 currently pending
Career history
453
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
42.9%
+2.9% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
31.0%
-9.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 408 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This office action is responsive to the amendment filed on 11/24/2025. As directed by the amendment: claims 1, 10, 12, and 16 have been amended, claims 18-20 have been cancelled and claims 21-23 have been added. Thus, claims 1-17 and 21-23 are presently pending in this application. Election/Restrictions Claims 12-17 and 22 are withdrawn as being drawn to non-elected species II. Elected species I is a primary covering over at least a portion of a frame and a secondary cover that covers parts of the frame not covered by the primary covering. Claim 12 has been amended to recite “the primary covering partially overlaps the secondary covering” which is not part of elected species I. Response to Arguments Applicant’s arguments, see pg. 6-7, filed 11/24/2025, with respect to the rejection(s) of claim(s) 1 under 35 U.S.C. 102 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Mellmann and Hewitt. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-11, 21, and 23 are rejected under 35 U.S.C. 103 as being unpatentable over Mellmann et al. (US 20170258475 A1) in view of Hewitt et al. (US 20160249934 A1). Regarding claim 1 Mellmann discloses (fig. 1-7A) an implantable medical device, comprising: an expandable frame 1 defining a profile of the implantable medical device (see fig. 3b and [0083]-[0085]), the expandable frame 1 movable between a collapsed configuration (fig. 3b) for delivery and an expanded configuration (fig. 5b) for deployment (see [0051] and [0053]), the expandable frame including a proximal portion (portion adjacent 3), a distal portion (portion adjacent 2) and an intervening intermediate portion (portion therebetween, see fig. 4b); a primary covering (4+6) extending over the proximal portion of the expandable frame (see fig. 4b and [0091]-[0092]); and a secondary covering 7 extending over parts of the expandable frame not covered by the primary covering (see fig. 4b and [0091]-[0092]). Mellmann further teaches that the primary covering can be stiffer / less elastic than the secondary covering (see [0101]). Mellmann fails to expressly disclose the primary covering has a first density and the secondary covering has a second density less than the first density. However Hewitt, in the same filed of endeavor, teaches (fig. 56 and 58) of a primary covering 1304 on proximal side of the device and a secondary covering 1302 on the distal portion of the device (see fig. 56, 58, and [0290]), wherein the primary covering 1304 has a first density (BD.sub.avg2) and the secondary covering 1302 has a second density (BD.sub.avg1) less than the first density (see [0290]). Therefore it would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to modify Mellmann to have the primary covering has a first density and the secondary covering has a second density less than the first density as taught by Hewitt, for the purpose of having a higher density portion to block blood flow into the defect and a lower density portion to be able to collapse the distal end of the device to a smaller diameter to improve delivery (see Hewitt [0290] and [0292]). Regarding claim 2, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) the secondary covering 7 extends over the intermediate portion of the expandable frame (see fig. 4b). Regarding claim 3, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) the secondary 7 covering extends over the distal portion (portion adjacent 2) of the expandable frame (see fig. 4b). Regarding claim 4, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) the expandable frame comprises a plurality of proximal anchors 8 disposed about a first periphery of the expandable frame (see fig. 3b and [0092]). Regarding claim 5, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 4. Mellmann further discloses (fig. 1-7A) the expandable frame comprises a plurality of distal anchors 9 disposed about a second periphery of the expandable frame, the second periphery displaced axially from the first periphery (see fig. 3b). Regarding claim 6, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 5. Mellmann further discloses (fig. 1-7A) the primary covering 4+6 is secured in place relative to the expandable frame via interactions between the primary covering and the plurality of proximal anchors 8 (see fig. 3b and [0092]). Regarding claim 7, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 5. Mellmann further discloses (fig. 1-7A) the secondary covering 7 is secured in place relative to the expandable frame via interactions between the secondary covering and the plurality of distal anchors 9 (see fig. 3b and [0092]). Regarding claim 8, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) the secondary covering 7 is secured in place relative to the expandable frame 1 via sutures 9 extending between the secondary covering and the expandable frame (see fig. 3b and [0092]). Regarding claim 9, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) the secondary covering 7 is secured in place relative to the expandable frame via sutures 70 extending between the primary covering and the secondary covering (see fig. 3b and [0092]). Regarding claim 10, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann as modified teaches the primary covering has a first thickness and the secondary covering has a second thickness less than the first thickness. (Hewitt teaches the section where fewer filaments overlap results in a reduced thickens, see [0304], and the secondary covering 1302 has less filaments overlapping than the primary covering 1304 resulting in a second thickness less than the first thickness, see fig. 56. Mellmann is modified to have the secondary covering have a lower density which also results in the secondary covering having less overlapping filaments). Regarding claim 11, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) an LAAC (left atrial appendage closure) device (see abstract). Regarding claim 21, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses the primary covering is a fabric, the secondary covering is a fabric (see [0101]). Mellmann as modified is silent regarding the primary covering having a first Denier rating of 20 to 25 and the secondary covering having a second Denier rating of 10 to 15. However, it would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Mellmann as modified to have the primary covering having a first Denier rating of 20 to 25 and the secondary covering having a second Denier rating of 10 to 15 since it has been held that “where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device” Gardner v. TEC Syst., Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 SPQ 232 (1984). In the instant case, the device of Mellmann as modified would not operate differently with the claimed Denier as the covers would still perform their function of occluding. Further, applicant places no criticality on the range claimed, indicating simply that the Denier “may” be within the claimed ranges (specification [0067]). Regarding claim 23, Mellmann as modified discloses the claimed invention substantially as claimed, as set forth above for claim 1. Mellmann further discloses (fig. 1-7A) the primary covering (4+6) has a first knit pattern (woven) and the second covering 7 has a second knit pattern (knitted) different from the first knit pattern (see [0101]). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE H SCHWIKER whose telephone number is (571)272-9503. The examiner can normally be reached Monday - Friday 7:30 am-4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at (571) 272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE H SCHWIKER/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Jul 20, 2023
Application Filed
Aug 20, 2025
Non-Final Rejection — §103
Nov 24, 2025
Response Filed
Mar 09, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594070
SUTURING DEVICE WITH IMPROVED NEEDLE TRANSFERRING MECHANISM
2y 5m to grant Granted Apr 07, 2026
Patent 12588921
TREATMENT TOOL, TREATMENT TOOL ASSEMBLING METHOD, AND TREATMENT TOOL DISASSEMBLING METHOD
2y 5m to grant Granted Mar 31, 2026
Patent 12569252
SYSTEMS AND METHODS FOR TREATING ANEURYSMS
2y 5m to grant Granted Mar 10, 2026
Patent 12564392
CONTAINMENT BAG
2y 5m to grant Granted Mar 03, 2026
Patent 12558090
MULTI-FIRE FASTENER DELIVERY SYSTEM AND METHOD
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+35.5%)
3y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 408 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month